## ZTS: Zoetis Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 0.1% below STRENGTH zone (4.0-10.0%); PEG 2.30 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-2.6% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($117.38)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 1
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. The Zacks Analyst Blog Highlights Cardinal Health, Medtronic, Intuitive Surgical and Edwards Lifesciences**
- Source: The Globe and Mail | 20251223T163641 | Neutral | Relevance: 59%
- This Zacks Analyst Blog highlights four large-cap MedTech companies—Cardinal Health, Medtronic, Intuitive Surgical, and Edwards Lifesciences—poised for continued growth in 2026. The MedTech industry has shown resilience, with factors like AI expansion, minimally invasive procedures, and normalizing procedure volumes driving its growth. These companies are well-positioned to maintain their winning streak due to diversified portfolios, strong execution, and innovation in their respective medical technology fields.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Barclays | $136 | $0 | 0% |
| 2025-12-03 | BTIG | $160 | $160 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Barclays | init | Equal-Weight |
| 2025-12-03 | BTIG | reit | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 8 ($0.32M) |
| Sells | 1 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 38.6% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 2 / 7 |

**Top Holders:**
- Vanguard Group Inc: 9.6% (+1.0%)
- Blackrock Inc.: 8.2% (-2.8%)
- State Street Corpora: 4.5% (-0.5%)
- Morgan Stanley: 3.8% (-4.3%)
- State Farm Mutual Au: 3.6% (0.0%)

### Key Risks

1. Long-term trend broken: trading 16.7% below SMA200.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 2.30 elevated, pricing in significant growth expectations. Forward P/E 18.2x stretched relative to 7% growth. Quality metrics strong (ROE 50%, ROA 15%, margin 28%). Balance sheet: strong liquidity (3.6x). Institutional flow bearish (7 selling vs 2 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $54.8B |
| Beta | 0.97 |
| 52W Range | $115.25 - $177.40 |
| Short Interest | 2.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.30 |
| Forward P/E | 18.2 |
| Current P/E | 19.5 |
| YoY Growth | 6.9% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 2.6% to 0.1% (-2.6% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 3.9pp (needs >4.0% for momentum thesis). MRS_5 (-1.1%) diverging from MRS_20 - short-term weakness emerging. Below SMA200 (0.83x), long-term trend not supportive. MACD histogram positive (0.99), confirming momentum. RSI neutral at 50. OFD pattern: +DLL (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 0.06% (CS: 57) | Neutral |
| RSI_14 | 50.5 | Neutral |
| MACD Histogram | 0.99 | Bullish |
| vs SMA20 | 1.011x | Above |
| vs SMA50 | 0.962x | Below |
| vs SMA200 | 0.833x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $123.54
- **Stop Loss:** $117.38 (5.0% risk)
- **Target:** $129.70 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 194
- **Position Value:** $23,966.76
- **Portfolio %:** 23.97%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite in holiday-thinned conditions. VIX at 52-week lows suggests complacency, but modest breadth improvement and stable yields indicate underlying stability. Focus on quality positioning ahead of 2026 catalysts.*

### Earnings

**Next:** 2026-02-12 (Est: $1.40)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.62 | $1.70 | +4.8% |
| 2025Q2 | $1.61 | $1.76 | +9.2% |
| 2025Q1 | $1.40 | $1.48 | +5.8% |
| 2024Q4 | $1.36 | $1.40 | +2.8% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*